Table 14-A
Single-year Prostate Cancer Incidence by Stage at Diagnosis
Michigan Male Residents, 1985-2020
Year of
Diagnosis
Total In Situ Localized Regional Distant Unknown
Number Percent Number Percent Number Percent Number Percent Number Percent
2020 7,4391-5,51674.196713.05227.04335.8
2019 8,0482-5,82472.41,09413.65346.65947.4
2018 7,3111-5,34973.21,08414.85247.23534.8
2017 7,0132-4,84469.11,07915.44246.06649.5
2016 6,9641-4,86069.81,03914.94226.16429.2
2015 6,5991-4,73471.795114.43585.45558.4
2014 6,237--4,47071.790314.53275.25378.6
2013 6,310--4,78875.984413.43074.93715.9
2012 6,825--5,15675.593713.72874.24456.5
2011 8,9152-7,08579.51,10612.42973.34254.8
2010 8,3702-6,58678.71,11213.33053.63654.4
2009 8,2392-6,72581.691011.02593.13434.2
2008 8,2854-6,66280.484710.22633.25096.1
2007 9,0302-7,39981.98589.52282.55436.0
2006 8,4183-6,67079.28229.82703.26537.8
2005 7,7532-6,09578.67619.82353.06608.5
2004 8,15460.16,34277.88109.92062.57909.7
2003 8,40850.16,50677.47539.02132.593111.1
2002 9,19090.17,22178.68228.92242.49149.9
2001 8,957140.26,77075.67408.32252.51,20813.5
2000 8,859330.46,73976.17378.32743.11,07612.1
1999 8,820390.46,45073.17788.82312.61,32215.0
1998 7,931180.25,56770.27259.13003.81,32116.7
1997 7,739200.35,33769.078210.13053.91,29516.7
1996 7,263210.35,13370.77169.93224.41,07114.7
1995 7,230220.34,78566.283011.53494.81,24417.2
1994 7,865460.64,89762.384510.73514.51,72621.9
1993 9,213350.45,54160.11,22513.34855.31,92720.9
1992 9,977750.86,14861.61,26612.76016.01,88718.9
1991 8,458690.84,95858.61,06712.66527.71,71220.2
1990 6,391230.43,48954.680412.664210.01,43322.4
1989 5,160330.62,64351.264012.462712.21,21723.6
1988 4,677320.72,53854.365614.059612.785518.3
1987 4,474410.92,50355.94379.859313.390020.1
1986 3,838280.72,15356.13519.159715.670918.5
1985 3,608250.72,07357.53018.356515.764417.8

Table 14-B
Five-year Prostate Cancer Incidence by Stage at Diagnosis
Michigan Male Residents, 1985-2020
Year of
Diagnosis
Total In Situ Localized Regional Distant Unknown
Number Percent Number Percent Number Percent Number Percent Number Percent
2016-2020 36,7757-26,39371.85,26314.32,4266.62,6867.3
2015-2019 35,9357-25,61171.35,24714.62,2626.32,8087.8
2014-2018 34,1245-24,25771.15,05614.82,0556.02,7518.1
2013-2017 33,1234-23,69671.54,81614.51,8385.52,7698.4
2012-2016 32,9352-24,00872.94,67414.21,7015.22,5507.7
2011-2015 34,8863-26,23375.24,74113.61,5764.52,3336.7
2010-2014 36,6574-28,08576.64,90213.41,5234.22,1435.8
2009-2013 38,6596-30,34078.54,90912.71,4553.81,9495.0
2008-2012 40,63410-32,21479.34,91212.11,4113.52,0875.1
2007-2011 42,83912-34,45780.44,83311.31,3523.22,1855.1
2006-2010 42,34213-34,04280.44,54910.71,3253.12,4135.7
2005-2009 41,72513-33,55180.44,19810.11,2553.02,7086.5
2004-2008 41,64017-33,16879.74,0989.81,2022.93,1557.6
2003-2007 41,76318-33,01279.04,0049.61,1522.83,5778.6
2002-2006 41,923250.132,83478.33,9689.51,1482.73,9489.4
2001-2005 42,462360.132,93477.63,8869.21,1032.64,50310.6
2000-2004 43,568670.233,57877.13,8628.91,1422.64,91911.3
1999-2003 44,2341000.233,68676.23,8308.71,1672.65,45112.3
1998-2002 43,7571130.332,74774.83,8028.71,2542.95,84113.3
1997-2001 42,3061240.330,86373.03,7628.91,3353.26,22214.7
1996-2000 40,6121310.329,22672.03,7389.21,4323.56,08515.0
1995-1999 38,9831200.327,27270.03,8319.81,5073.96,25316.0
1994-1998 38,0281270.325,71967.63,89810.31,6274.36,65717.5
1993-1997 39,3101440.425,69365.44,39811.21,8124.67,26318.5
1992-1996 41,5481990.526,50463.84,88211.82,1085.17,85518.9
1991-1995 42,7432470.626,32961.65,23312.22,4385.78,49619.9
1990-1994 41,9042480.625,03359.75,20712.42,7316.58,68520.7
1989-1993 39,1992350.622,77958.15,00212.83,0077.78,17620.9
1988-1992 34,6632320.719,77657.14,43312.83,1189.07,10420.5
1987-1991 29,1601980.716,13155.33,60412.43,11010.76,11721.0
1986-1990 24,5401570.613,32654.32,88811.83,05512.45,11420.8
1985-1989 21,7571590.711,91054.72,38511.02,97813.74,32519.9

Notes:

In Situ Stage represents the presence of malignant cells within the cell group from which they arose, with no penetration of basement membrane of the tissue and no stromal invasion.
Localized Stage represents invasive cancer confined to the organ of origin or intralumenal extension where specified as an intralumenal extension to immediately contiguous segments of the large bowel.
Regional Stage represents direct extension to adjacent organs or tissues or involvement of the regional lymph nodes.
Distant Stage represents direct continuity to non-adjacent organs, discontinuous metastasis or involvement of the distant lymph nodes.
COVID-19 Pandemic: In 2020, the highly publicized impact of the COVID-19 pandemic on health services and the consequential delays and reductions in cancer screening and diagnosis led to a decline in the 2020 incidence rates for most cancer sites. Because 2020 was a temporary, anomalous year, it can bias estimates such as cancer incidence trends.
Source : Michigan Resident Cancer Incidence File. Updated with cases processed through November 30, 2022. Division for Vital Records & Health Statistics, Michigan Department of Health & Human Services.

Last Updated : April 13, 2023
Select similiar cancer tables for your community.